Effective December 15, 2025, CARDIOFLOW-B (02160) announced the following board committee changes: Mr. Chen Guoming, Non-Executive Director and Board Chairman, has been appointed as a member of the Audit Committee and will no longer serve on the Remuneration Committee or as Chairman of the Nomination Committee. Dr. Hu Bingshan, Independent Non-Executive Director, has been reassigned as Chairman of the Nomination Committee and appointed to the Remuneration Committee, while stepping down from the Audit Committee. Dr. Brian Chang, Non-Executive Director, has joined the Nomination Committee.

The Board resolved to establish a Strategic Committee under its purview, effective December 15, 2025. The committee will focus on researching and advising the company’s long-term development strategies and major strategic decisions. Comprising six members—Dr. Brian Chang (Chairman), Mr. Chen Guoming, Mr. Zhang Ruinian, Mr. Philippe Wanstok, Mr. Deng Aoyi, and Dr. Hu Bingshan—the committee aims to enhance strategic oversight.

Additionally, the Board approved the formation of a Commercialization Committee, effective the same date, to optimize planning and execution of the company’s commercialization framework. This committee will strengthen market competitiveness across product commercialization phases. Its five members include Mr. Chen Guoming (Chairman), Dr. Brian Chang, Mr. Zhang Ruinian, Mr. Philippe Wanstok, and Ms. Wu Xia.